home
about us
our story
OUR MISSION
OUR VALUES
OUR PARTNERS
OUR SCIENTIFIC CO-FOUNDERS
OUR MANAGEMENT
OUR BOARD
TALENTS
science
F prau.
in Iflammatory Bowel Diseases
F prau.
in Cancer
MANUFACTURING LIVE BIOThERAPEUTICS
pipeline
Overview
Patients
Exl01 in Crohn's diseases
Exl01 in Cancer Immunotherapy
newsroom
PUBLICATIONS
contact
menu
about us
about us
Our story
Our mission
Our values
Our partners
Our Scientific Co-founders
Our management
Our board
Talents
science
science
Exl01
Crohn's Disease
Faecalibacterium Prausnitzii
in Inflammatory Bowel Diseases
Faecalibacterium Prausnitzii
immuno-oncology
Faecalibacterium Prausnitzii
in Recurrent
Clostridium difficile
Infections
Tryptophan metabolism
Manufacturing Live Biotherapeutics
pipeline
pipeline
OVERVIEW
Patients
EXL01 in Crohn’s Disease
EXL01 in Cancer Immunotherapy
EXL01 in Immuno-Oncology
EXL01 in recurrent
Clostridium difficile
infections
EXL02
EXL03
Regulatory Expertise
Intellectual Property
newsroom
newsroom
Corporate Presentation
Publications
News
Upcoming Events
contact
Paris Biotech Santé
Sep 25, 2017
Exeliom Biosciences joins Paris Biotech Santé Incubator
Back to news
Series-A Biotech Exeliom Biosciences Nextbiotix
Jul 5, 2018
Exeliom Biosciences (formerly Nextbiotix) raises €7 million to tackle inflammatory bowel diseases
Explore
Clinical Trial Live Biotherapeutics Crohn's Disease Belgium
Feb 24, 2022
Exeliom Biosciences announces approval of Clinical Trial Application from the Belgian Agency for Single Strain Live Biotherapeutic EXL01 (Faecalibacterium prausnitzii) for the treatment of Crohn’s Disease
Explore
Nextbiotix Exeliom Biosciences
Feb 15, 2019
Nextbiotix becomes Exeliom Biosciences
Explore
contact
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
